Management change

Arix Bioscience plc

Management change

LONDON, 2 October 2019: Arix Bioscience plc (“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces the departure of Chief Financial Officer, James Rawlingson and promotion of Group Financial Controller, Marcus Karia to Group Finance Director. These changes take place with immediate effect.

Joe Anderson, Chief Executive Officer commented:

“On behalf of the board I’d like to thank James for his contribution to Arix in the first stage of our development and wish him well in his future endeavours.”

Enquiries:

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

[phone]

[e-mail]  

Optimum Strategic Communications

Mary Clark, Supriya Mathur

[phone]

[e-mail]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

www.arixbioscience.com